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Dense deposit disease and glomerulonephritis with isolated
C3 deposits are glomerulopathies characterized by deposits
of C3 within or along the glomerular basement membrane.
Previous studies found a link between dysregulation of the
complement alternative pathway and the pathogenesis of
these diseases. We analyzed the role of acquired and genetic
complement abnormalities in a cohort of 134 patients,
of whom 29 have dense deposit disease, 56 have
glomerulonephritis with isolated C3 deposits, and 49 have
primary membranoproliferative glomerulonephritis type I,
with adult and pediatric onset. A total of 53 patients
presented with a low C3 level, and 65 were positive for C3
nephritic factor that was significantly more frequently
detected in patients with dense deposit disease than in
other histological types. Mutations in CFH and CFI genes were
identified in 24 patients associated with a C3 nephritic factor
in half the cases. We found evidence for complement
alternative pathway dysregulation in 26 patients with
membranoproliferative glomerulonephritis type I. The
complement factor H Y402H variant was significantly increased
in dense deposit disease. We identified one at-risk membrane
cofactor protein (MCP) haplotype for glomerulonephritis
with isolated C3 deposits and membranoproliferative
glomerulonephritis type I. Thus, our results suggest a critical
role of fluid-phase alternative pathway dysregulation in the
pathogenesis of C3 glomerulopathies as well as in immune
complex–mediated glomerular diseases. The localization of the
C3 deposits may be under the influence of MCP expression.
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Dense deposit disease (DDD) and glomerulonephritis with
isolated C3 deposits (GNC3) are characterized by glomerular
deposition of C3 and are associated with dysregulation of the
complement alternative pathway (AP).1–3 The essential
feature of DDD is the presence of electron-dense transforma-
tion of the glomerular basement membrane (GBM), and not
the membranoproliferative pattern.4 These dense deposits
contain components of the alternative pathway including
C3b and its breakdown products iC3b, C3dg, or C3c, and
terminal complement complex.5 Conversely, GNC3 are
characterized by subendothelial deposits containing exclu-
sively C3 products, without immunoglobulins and without
dense intramembranous deposits within the glomerular and
the tubular basement membranes.2,6–8 The AP dysregulation
in DDD and GNC3 is usually induced by C3 nephritic factor
(C3NeF), an autoantibody that stabilizes the AP C3
convertase.1 Only few patients with homozygous or hetero-
zygous mutations in the regulatory complement proteins
factor H (CFH), factor I (CFI), or C3 have been
identified.2,7,9,10 Particular variants of CFH (H402Y) and of
CFH-related 5 (CFHR5) may preferentially be associated
with DDD.11–13 On the basis of etiology, DDD and GNC3 are
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classified as complement-mediated disease. However, few
clinical series with complement analysis have been reported,
and in particular no frequencies of acquired or genetic
abnormalities are available.13,14 If the uncontrolled activation
of the AP in fluid phase seems a common feature between the
two diseases, no biological or genetic markers influencing the
location of the dense deposits have been identified.
In contrast, primary membranoproliferative glomerulone-
phritis type I (MPGN I) is an immune complex glomerulone-
phritis that may be complement mediated and is characterized
by deposits containing immunoglobulins and classical pathway
components. Despite one report of MPGN I associated with
complete CFH deficiency,9 the influence of the AP in this
disease remains unclear. Recent observations in CFH knockout
mouse model suggest that AP may also play a critical role in
immune complex–mediated glomerular diseases.15 Therefore,
we hypothesized that acquired or genetic complement
abnormalities may also predispose to MPGN I.
The aim of this study was to evaluate the clinical features
and the relative role of acquired (C3NeF) and genetic (CFH,
CFI, and membrane cofactor protein (MCP)) complement
abnormalities in a large cohort of patients with DDD, GNC3,
and MPGN I. Patients were genotyped to determine whether
specific polymorphisms or haplotypes in CFH and MCP
genes segregate preferentially with the disease phenotype.
RESULTS
Clinical data at diagnosis
Clinical and biological data for the patients at diagnosis are
summarized in Table 1. This French multicentric cohort
included 134 patients from 130 pedigrees. There were 52
patients (39%) with early onset (before 16 years of age).
There was a familial history of glomerulonephritis in 15
cases. Two affected relatives from each of four families (8 of
the 15 cases with family history) were included in this study.
Renal symptoms at diagnosis included: acute renal failure
in 3 cases, stage 5 kidney disease in 15 cases, stage 4 in 7 cases,
stage 3 in 17 cases, stage 2 in 19 cases, and stage 1 in the other
cases. The hepatitis C serology was negative in all patients.
There was no associated autoimmune disease and no
monoclonal gammopathy. Partial lipodystrophy was observed
in five patients with DDD.
Pathological data
A total of 35 patients had more than one biopsy of native
or transplant kidney. DDD was diagnosed in 29 patients
(Figure 1a–d). It was defined as thickening of capillary walls
due to both GBM deposits and double contours (light
microscopy), deposits (mainly C3) in the GBM (immuno-
fluorescence study), and thickening of the GBM due to
electron-dense deposits within the lamina densa (electron
Table 1 | Clinical and biological data according to histological type
All MPGN 1 DDD GNC3 P-value
N 134 49 29 56
Sex (M/F) 81/53 (60.4%) 32/17 (65.3%) 17/12 (58.6%) 33/24 (58.9%) NS
Childrena/adults 52/82 (38.8%) 21/28 (42.8%) 17/12 (58.6%) 14/42 (25.0%) NS
Age at diagnosis (years) 24.3±18.6 20.7±16.8 18.9±17.7 30.3±19.3 o0.05c and o0.01d
Proteinuria (g/day) 4.9±4.1 6.9±4.4 5.6±4.5 3.6±3.3 o0.05c
Nephrotic syndrome 58 (41.1%) 32 (65.3%) 11 (37.9%) 15 (26.8%) o0.0001c and 0.02e
Microhematuria 83 (58.8%) 25 (51.0%) 22 (75.8%) 36 (64.3%) NS
HBP 43 (30.5%) 16 (32.6%) 6 (20.7%) 21 (37.5%) NS
eGFR (ml/min per 1.73m2) 69.3±36.6 73.7±33.7 75.5±38.8 65.9±37.4 NS
ACE inhibitor/ARB treatment 64 (45.4%) 27 (55.1%) 10 (34.5%) 27 (48.2%) NS
Immunosuppressive treatment 61 (43.2%) 28 (57.1%) 14 (48.3%) 19 (33.9%) 0.02c
Follow-up (years) 11.2±11.2 11.7±12.0 12.0±12.1 10.2±10.1 NS
At last follow-up
eGFR (ml/min per 1.73m2) 50.4±39.5 47.7±40.3 53.8±40.3 50.9±37.1 NS
Proteinuria (g/day) 2.2±2.7 2.4±3.5 1.4±1.6 2.1±2.4 NS
Nephrotic syndrome 19 (14.1%) 8 (16.3%) 2 (6.9%) 9 (16.1%) NS
Duration of evolution until ESRDb (years) 10.3±10.2 10.1±9.8 9.8±11.6 10.8±10.0 NS
Dialysis 49 (36.6%) 20 (40.8%) 12 (41.4%) 17 (30.3%) NS
Age at dialysis (years) 35.6±17.6 30.3±17.2 36.9±18.1 40.8±16.9 NS
Renal transplantation 35 (26.1%) 14 (28.6%) 11 (37.9%) 10 (17.8%) NS
K Recurrence 18 (51.4%) 6 (42.8%) 6 (54.5%) 6 (60%) NS
K Thrombotic microangiopathy 6 (17.1%) 2 (14.3%) 3 (27.3%) 1 (10.0%) NS
K Vascular rejection 2 (5.8%) 1 (7.1%) 0 (0%) 1 (10.0%) NS
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin-receptor blocker; DDD, dense deposit disease; eGFR, estimated glomerular filtration rate (Modification
of Diet in Renal Disease); ESRD, end-stage renal disease; F, female; GNC3, glomerulonephritis with isolated C3 deposits; HBP, high blood pressure; M, male;
MPGN, membranoproliferative glomerulonephritis; N, number; NS, not significant.
aBelow 16 years of age.
bIf ESRD.
cP-value: MPGN 1 compared with GNC3.
dP-value: DDD compared with GNC3.
eP-value: MPGN 1 compared with DDD.
Mean±s.d., number (percentage).
Nephrotic syndrome was defined as a serum albumin concentration below o3 g/dl and proteinuria 43 g/day.
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microscopy). All cases of DDD showed these classical
intramembranous dense deposits. Among them, 17 had
mesangial cellular proliferation and 9 had crescents.
MPGN I was diagnosed in 48 patients (Figure 1e–h) and
MPGN III in 1 patient who was included in the MPGN I group
for further analysis. MPGN I was defined as mesangial cellular
proliferation, increase in the mesangial matrix, a diffuse
‘double contours’ aspect and subendothelial, and mesangial
deposits (light microscopy), C3 and significant granular
immunoglobulin (Ig) deposits in mesangial area, mainly IgG
and sometimes C1q, IgM, and/or IgA (immunofluorescence
study), and subendothelial and mesangial deposits (electron
microscopy). Crescents were observed in eight cases.
GNC3 was found in 56 cases (Figure 1i–l), defined as
mesangial and epimembranous deposits containing only C3
without Ig deposits (immunofluorescence study) with or
without membranoproliferative pattern, and without dense
deposits within the GBM (electron microscopy). In 71% of
the GNC3 cases, renal biopsy showed a membranoprolifera-
tive pattern with mesangial proliferation, subendothelial,
mesangial, and, less frequently, epimembranous deposits,
diffuse ‘double contours’ aspect, and accumulation of
mesangial matrix. In 29% of the cases (16 patients), renal
biopsy disclosed mesangial and epimembranous deposits
without subendothelial deposits or mesangial proliferation.
Crescents were observed in 10 cases. In all cases, immuno-
fluorescence study revealed isolated C3 deposits without
dense intramembranous deposits.
Table 2 reports pathology according to genetic defects and
Table 3 reports MPGN 1 cases with C3NeF.
Figure 1 | Illustrative cases of dense deposit disease (DDD), membranoproliferative glomerulonephritis type I (MPGN I), and
glomerulonephritis with isolated C3 deposits (GNC3) by light microscopy, immunofluorescence study, and electron microscopy.
(a) DDD with mesangial proliferation and ribbon-like aspect of the glomerular basement membranes (light green trichrome,  250).
(b) DDD with mesangial deposits and characteristic aspect of the glomerular basement membranes (Jones’ staining,  1000). (c) DDD with
mesangial C3 deposits and a mild fixation along the glomerular basement membranes by immunofluorescence study ( 250). (d) DDD with
electron-dense transformation of the lamina densa by electron microscopy (uranyl acetate and lead citrate,  2500). (e) MPGN I with
mesangial proliferation and endomembranous deposits (light green trichrome,  250). (f) MPGN I with immunoglobulin G (IgG) deposits
along the glomerular basement membranes and in the mesangial space by immunofluorescence study ( 250). (g) MPGN I with C3
deposits in the same localization as IgG by immunofluorescence study ( 250). (h) MPGN I with subendothelial deposits by electron
microscopy (uranyl acetate and lead citrate,  2500). (i) GNC3 with endomembranous deposits and granular deposits in the mesangial
space (light green trichrome,  250). (j) GNC3 with double contours and complex changes of the glomerular basement membranes
(Jones’ staining,  250). (k) GNC3 with C3 deposits (and without immunoglobulin) by immunofluorescence study ( 250). (l) GNC3
with subendothelial, mesangial, and some epimembranous deposits without transformation of the lamina densa by electron
microscopy (uranyl acetate and lead citrate,  2500).
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Complement component assessment
Plasma complement levels for 115 patients who did not
receive any immunosuppressive therapy at the time of the
investigations are shown in Table 4. At the time of the first
investigation, 59% and 40% of the DDD and GNC3 patients,
respectively, had a low C3 level and a normal C4, suggesting
an AP consumption (Figure 2a). A total of 20% of DDD and
GNC3 patients presented witho20% of normal C3. Low C3
but normal C4 levels were also observed in 46% of MPGN I
patients. A C3NeF was found in 58.6% of patients, fluctuating
during follow-up in 32% of them. Patients with C3NeF had a
significantly lower C3 level (P¼ 0.007; Figure 2b). Despite the
presence of C3NeF activity, C3 levels remained normal in 44%
of patients, and 34% of patients had low C3 levels despite no
C3NeF being detected. Nineteen patients (29.2%) with C3NeF
Table 3 | Complement component analysis and
immunofluorescence study of membranoproliferative
glomerulonephritis type I cases with positive C3 nephritic
factor
Patient
C3a (660 to
1250mg/l)
C4a (90 to
380mg/l)
CFBa (90 to
320mg/l) Histology
Immunofluores-
cence study
25 537b 160 83 MPGN I IgG, IgM, C3
26 512 127 50 MPGN I IgG, IgM, IgA, C3
27 183 178 225 MPGN I IgG, C3
28 701 233 96 MPGN I IgG, C3
29 87 202 51 MPGN I IgG, IgM, C3
30 847 222 71 MPGN I IgG, IgM, C3, C1q
31 48 126 89 MPGN I IgG, IgA, C3
32 87 309 92 MPGN I IgG, IgM, C3
33 293 209 100 MPGN I IgG, IgM, C3
34 180 248 123 MPGN I IgG, IgM, C3
35 193 95 126 MPGN I IgG, C3
36 275 225 159 MPGN I IgG, IgM, C3, C1q
37 1110 162 186 MPGN I NDc
38 475 175 155 MPGN I IgG, IgA, C3
39 741 169 82 MPGN I IgG, C3
40 875 273 124 MPGN I IgG, C3, C1q
41 135 182 130 MPGN I IgG, IgA, IgM, C3
42 129 227 64 MPGN I IgG, C3
Abbreviations: CFB, complement factor B; Ig, immunoglobulin; MPGN I, membra-
noproliferative glomerulonephritis type I; ND, not done.
aLaboratory reference values are indicated in brackets.
bRare variant CFI IVS 12+5 associated.
cBiopsy performed in 1974: lobular MPGN I, no immunofluorescence study available.
Cases with genetic abnormality are presented in Table 2.
Table 4 | Complement component assessment according to histological type
All MPGN 1 DDD GNC3
N 115 41 22 53
C3a (660 to 1250mg/l) 621.91±339.5 583.1±360.7 492.8±337.7 705.4±305.2
Low C3 (o660mg/l) 53 (46.1%) 19 (46.3%) 13 (59.1%) 21 (39.6%)
C4a (93 to 380mg/l) 227.9±86.3 198.4±65.7 204.8±88.9 260.8±89.3
Low C4 (o93mg/l) 2 (1.7%) 1 (2.4%) 1 (4.5%) 0
Factor Ba (90 to 320mg/l) 116.4±49.3 110.9±42.2 112.6±39.9 122.2±57.7
Low factor B (o90mg/l) 34 (29.6%) 14 (34.1%) 6 (27.3%) 14 (26.4%)
Low factor H (o338mg/l) 8 (6.9%) 2 (4.9%) 4 (18.2%) 2 (3.8%)
Low factor I (o42mg/l) 3 (2.6%) 3 (7.3%) 0 0
C3NeF 65 (58.6%)b 22 (53.6%) 19 (86.4%) 24 (45.3%)
Unexplained C3 o660mg/l 6 (5.2%) 1 (2.4%) 0 5 (9.4%)
Abbreviations: C3NeF, C3 nephritic factor; DDD, dense deposit disease; GNC3, glomerulonephritis with isolated C3 deposits; MPGN, membranoproliferative glomerulonephritis.
aNormal values are indicated in brackets.
bC3NeF determination was not available in four patients.
Patients under immunosuppressive therapy at the time of complement assessment were excluded from this analysis (N=19). Mean±s.d., number (percentage).
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Figure 2 |C3 level distribution. (a) Mean C3 level distribution
in dense deposit disease (DDD), glomerulonephritis with isolated
C3 deposits (GNC3), and membranoproliferative glomerulonephritis
type I (MPGN I) patients. *P¼ 0.02. The normal values of C3 are
660 to 1250mg/l (dashed lines). (b) C3 level distribution according
to the presence or absence of C3NeF. Patients with C3NeF had
a significantly lower C3 level. *P¼ 0.007. The normal values of
C3 are 660 to 1250mg/l (dashed lines).
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had low factor B levels. A C3NeF was more frequently
detected in DDD patients than in other histological types
(86.4% vs. 48.9%, P¼ 0.002).
Screening for genetic abnormalities
A mutation was found in the complement genes in 24 patients
(17.9%) from 22 pedigrees (16.9%; Tables 2 and 5). Of the
patients carrying mutations, 13 also had C3NeF. Four patients
had a homozygous CFH mutation, characterized by complete
CFH deficiency in three of the cases. A heterozygous CFH
mutation was found in 13 patients; 5 of them had low plasma
CFH concentrations, suggesting a type I mutation. CFH type I
mutations were spread throughout the gene. Two of the
mutations were short deletions; one was a nonsense mutation;
one affected the donor site in intron 11 and four were cysteine
substitutions. Four out of the six CFH type II mutations
clustered in SCR1 and 3. Two related patients carried
heterozygous CFH mutations and associated homozygous
type I C2 deficiency. Six patients carried heterozygous CFI
missense mutations and two of them had a low plasma FI
concentration. One patient carried a heterozygous mutation
in the MCP gene. A mutation in the CFH gene was found in 9
patients (7 families) of the 16 familial cases. In six patients,
despite a low C3 concentration (o660 mg/l), no complement
abnormality affecting CFH, CFI, or MCP was identified. None
of the mutations found in the CFH, CFI, and MCP genes was
identified in 100 healthy controls or recorded in the single-
nucleotide polymorphism (SNP) databanks. Eight patients
carried rare polymorphisms: p.Q950H (2/134) in the CFH
gene, IVS 12þ 5 (5/134) in the CFI gene, and A306V (1/134)
in the MCP gene. The p.Q950H, IVS 12þ 5, and A304V
variants were identified in 0.3%, 2%, and 1%, of normal
French controls, respectively.
MCP and CFH SNP and haplotype analysis
We genotyped 102 patients of the cohort and a control
population for 10 selected SNPs in the CFH and MCP genes.
The allelic frequency of each of these SNPs was determined and
compared between the controls and the DDD (n¼ 28), GNC3
(n¼ 46), and MPGN I (n¼ 28) groups. Allele frequency of
CFH Y402H showed a significant association with DDD group
(Po0.05), but failed to reach significance for GNC3 and
MPGN I groups. A significant association was found between
GNC3 or MPGN I and one SNP (652A4G) located in the
MCP promoter (P¼ 0.03 and 0.05, respectively; Table 6).
The CFH and MCP haplotype frequencies for the three
groups are shown in Table 7. MCPaaggt haplotype (652A,
366A, IVS978G, IVS12þ 638G, c.2232T) was significantly
increased in GNC3 and MPGN I vs. controls. MCPgaggt
haplotype (652G, 366A, IVS978G, IVS12þ 638G,
c.2232T) was significantly decreased in GNC3 and DDD vs.
controls. No significant difference for CFH haplotype frequen-
cies was observed.
Comparison of histological groups and clinical evolution
Disease presentation and evolution for the different histolo-
gical groups are reported in Tables 1 and 4. Mean age at
diagnosis was significantly higher for patients with GNC3
than for patients with MPGN I (Po0.05) or DDD (Po0.01).
Proteinuria was significantly higher for MPGN I patients
than for GNC3 patients (Po0.05). Furthermore, a larger
Table 5 |Mutations and rare variants in the complement
genes according to histological type
All MPGN 1 DDD GNC3
N 134 48 29 56
CFH mutations 17 (12.7%) 5 (10.4%)b 5 (17.2%)a 7 (12.5%)a
CFI mutations 6 (4.5%) 3 (6.2%) 0 3 (5.3%)
MCP mutation 1 (0.7%) 0 0 1 (1.8%)
Rare variants:
CFH (p.Q950H;SCR16) 2 (1.5%) 0 0 2 (3.6%)
CFI IVS 12+5 5 (3.7%) 2 (4.2%) 2 (6.9%) 1 (1.8%)
MCP (A306V) 1 (0.7%) 0 0 1 (1.8%)
Abbreviations: CFH, complement factor H; CFI, complement factor I; DDD, dense deposit
disease; GNC3, glomerulonephritis with isolated C3 deposits; MCP, membrane cofactor
protein; MPGN, membranoproliferative glomerulonephritis; N, number (percentage).
aIncluding one and
btwo homozygous mutations.
Rare variants in a cohort of 190 healthy donors: 0.3%.
Table 6 | Comparison of CFH and MCP SNP frequencies in patients with DDD, GNC3, and MPGN I vs. controls
Genotypes Allele frequencies
1/1 1/2 2/2 Sum 1 2 P-value OR (95% CI)
CFH c.1204T4C; p.Tyr402His (rs1061170)
Controls 93 106 40 239 0.61 0.39 NS
DDD 8 9 10 27 0.46 0.54 0.04 1.82 (1.3–3.2)
GNC3 14 17 12 43 0.52 0.48 NS
MPGN I 12 11 4 27 0.65 0.35 NS
MCP-652 A4G (rs2796267)
Controls 10 4 5 19 0.63 0.37 NS
DDD 10 4 5 19 0.63 0.37 NS
GNC3 26 13 5 44 0.74 0.26 0.035 0.57 (0.32–0.9)
MPGN I 16 9 2 27 0.76 0.24 0.05 0.5 (0.25–0.98)
Abbreviations: CFH, complement factor H; 95% CI, 95% confidence interval; DDD, dense deposit disease; GNC3, glomerulonephritis with isolated C3 deposits; MCP, membrane
cofactor protein; MPGN, membranoproliferative glomerulonephritis; NS, not significant; OR, odds ratio; SNP, single-nucleotide polymorphism.
The two SNPs with a significant association are represented.
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proportion of patients with MPGN I than with DDD
(P¼ 0.02) or GNC3 (Po0.0001) presented with nephrotic
syndrome. Mean age at last follow-up was 34.1±19.8 years.
The 10-year renal survival was 63.5% (Figure 3a). Renal
survival was similar in the three groups (Figure 3b). However,
in adults, cumulative renal survival as assessed with
Kaplan–Meier analysis was worse in patients with DDD than
in patients with MPGN I and GNC3 (P¼ 0.02; Figure 3c).
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After transplantation, six patients (17.1%) developed
thrombotic microangiopathy (one carried a CFI mutation)
and two (5.8%) vascular rejection. Two non-transplanted
patients also developed thrombotic microangiopathy, before
MPGN onset in one case and 1 year after in the other case.
Genetic screening showed a CFH and a CFI mutation,
respectively. Recurrence occurred in 18 patients (51%): 3 of
these patients had a C3NeF and none a mutation.
Risk factors of progression to renal insufficiency
The glomerular filtration rate (GFR) at diagnosis correlated
well with GFR at last follow-up (Po0.0001). Renal survival
was worse if the GFR at diagnosis was o60 ml/min per
1.73 m2 than if renal function was normal (P¼ 0.03). GFR at
last follow-up was inversely correlated with age at diagnosis
(P¼ 0.003). By multivariate analysis, GFR and age at diagnosis
were correlated with GFR at last follow-up (P¼ 0.003 and
P¼ 0.001). Cumulative renal survival by Kaplan–Meier
analysis did not differ between patients with normal, low C3
concentration (o600 mg/l), and very low C3 concentration
(o200 mg/l).
By univariate analysis, the use of angiotensin-converting
enzyme inhibitors or angiotensin receptor blockers was
associated with a better renal survival (Po0.0001), but not
the use of immunosuppressive agents.
DISCUSSION
We report protein analysis and genetic screening of comple-
ment AP control proteins in a series of 134 patients with
three subtypes of glomerulonephritis with C3 deposits,
including cases of DDD, GNC3, and MPGN I, with both
adult and pediatric onset. As far as we are aware, this is the
largest series describing the clinicopathological characteristics
and outcome of these three distinct pathological patterns of
glomerulonephritis and their relationship with complement.
We found a defective complement control due to acquired
(C3NeF) or hereditary abnormalities of the control proteins
of the complement AP in 71% of the patients. Furthermore,
for the first time, we identified one at-risk MCP haplotype
that influences the histological pattern. These results high-
light that MCP, which is expressed on endothelial and
mesangial cells and participates to the generation of the C3
metabolite iC3b, is implicated in the glomerular changes in
patients presenting fluid-phase activation of complement.
Loss of AP control seems to be required for the
pathogenesis of lesions in DDD and GNC3.1–3 In all patients,
granular C3 deposits are present within the mesangium and/or
along the GBM in the subendothelial area (GNC3) or within
the GBM (DDD), reflecting complement C3 convertase
activation. There have been only two studies in recent years
evaluating the clinical characteristics of the disease.14,27
Particularly, little is known about the course in adults.28 C3
glomerulopathies are associated with chronic deterioration of
renal function, leading to end-stage renal disease within 10
years of the diagnosis in 36.5% of patients in our series and
approximately half of the patients in previous series.14,27–31
Interestingly, renal survival was similar in the three groups. Of
the patients with DDD, 41% progressed to end-stage renal
disease, consistent with 47% of such patients in another
cohort.14 Our data confirmed that adults with DDD are more
likely to suffer from a rapid decline in renal function than
children.28 Renal failure at diagnosis was associated with an
adverse prognosis, as already documented.14,32 Our series also
shows that all these glomerulopathies can present over a broad
age range. A central review of the biopsies could be performed
in 45.5% of the biopsies but not in all of them, which is
a potential weakness of the study. The optimal treatment
remains undefined, partly because there have been no
appropriate trials. In this large retrospective study, we found
that renin angiotensin blockade was associated with a better
renal survival, but not immunosuppressive treatment. How-
ever, Nasr et al.14 reported that combined immunosuppressive/
renin angiotensin blockade was better than either agent alone
in DDD.
In both DDD and GNC3, acquired and genetic comple-
ment AP abnormalities have been reported in small series or
in anecdotal reports.2,7–13 First described in DDD, but not
specific for this disease, C3NeF binds and stabilizes the fluid
phase and the membrane-bound C3 convertases.33 In our
series, at the time of the first investigations, C3NeF activity is
found in 86% of patients with DDD and in 49% of patients
with MPGN I or GNC3. This is in line with previous findings
in DDD patients.1,31,34 The frequency may be variable as we
observed a fluctuation of the C3NeF activity in one-third of
the patients during follow-up. In most reported DDD
patients, C3NeF was typically associated with low C3 levels
in plasma.14,27 In our study, C3NeF is not always associated
with evidence of complement consumption in plasma.
Indeed, C3 remains in the normal range in B40% of
patients, suggesting the capacity of complement proteins to
regulate the C3NeF-stabilized C3 convertase. The strong
correlation between the complement and these glomerulop-
athies is further supported by the detection of mutations in
the complement regulators CFH and CFI. We identified a
genetic abnormality in complement genes in 18% of tested
patients, with half of these patients also being C3NeF
positive. The absence of FH in plasma as a cause of C3
glomerulopathies has been observed in humans, pigs, and
mice.2,35,36 However, complete CFH deficiency accounts for
only a small minority of reported cases described in the
literature and o5% of cases in our series (4 cases). We
identified heterozygous mutations in CFH and CFI associated
with low protein levels, suggestive of a quantitative deficiency
(type I mutations). Other mutations were found in patients
with normal CFH levels (type II mutations). For some of
them, a functional deficiency was suggested as they mapped
near the C3b-binding sites and may affect the generation of
the C3b metabolites. The remaining mutations in CFH and
CFI map far from known functional regions, and further
analyses are needed to determine their consequences.
Interestingly, CFH deficiency (complete and quantitative) is
also frequently found in patients with atypical hemolytic
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uremic syndrome (aHUS). In our series, we found three type
II mutations in CFH (R53C, A161S, and R1210C) and five
mutations in CFI (G101R, A222G, G243D, I288S, and I398L),
which have been previously identified in patients with
aHUS.23,37 These genetic data support the hypothesis that
the mutations in the complement AP genes by themselves are
not sufficient to determine the disease phenotype.
In order to study how the genetic background of the
patients influences the disease manifestation, we system-
atically analyzed the genetic variability in two regions of the
regulators of complement activation gene cluster, carrying
the genes for several complement regulators, including CFH
and MCP. CFH Y402H variant was significantly increased in
DDD vs. controls, which is consistent with previous data.8,13
Despite a trend for the influence of CFH haplotype H1, no
significant difference was found for the distribution of the
CFH haplotypes between our DDD patients and the normal
controls, in contrast to a previous report.12 One reason for
this discordance may be the difference of the frequency of the
CFH haplotypes in the control group population. The CFH
Y402H variant is highly associated with an increased risk for
development of age-related macular degeneration.38 DDD
glomeruli contain breakdown products of C3b without factor
B, suggesting that the major site of AP activity is the fluid
phase.5 The functional difference between Y and H at
position 402 of CFH remains unclear.39–42 The at-risk
Y402H does not affect the fluid-phase complement control,
but seems to confer a poorer regulation of the C3 convertase
on cell surface or in the GBM. The increasing generation of
iC3b and C3d in the circulation, due to the presence of
C3Nef or CFH mutations, may lead to their direct
accumulation in the GBM. Despite the small numbers of
cases in our series, it is worth noting that none of the patients
with DDD presented with a genetic abnormality in the CFI
gene. This may suggest a role of CFI in the accumulation of
C3 degradation products in the GBM and a key role for iC3b
in the pathogenesis of DDD. Indeed, it has been demon-
strated that the subendothelial C3 deposits do not develop in
mice with combined FH and FI deficiency.43 Therefore, FI-
mediated generation of activated C3 fragments in the
circulation under the influence of FH is a critical determinant
of the location of the deposits.
Our report is the first study that analyzes the frequency of
the MCP SNPs and haplotypes in C3 glomerulopathy
patients. We identified one at-risk MCP haplotype (aaggt),
which is significantly increased in GNC3 and MPGN I. This
haplotype is different from the ones identified in
aHUS.12,44,45 Therefore, although genetic abnormalities are
similar in C3 glomerulopathies and aHUS, the genetic
background of the patients seems to play an important role
in the disease phenotype. Studies in Cfh-deficient mice have
shown that the development of C3 deposits requires the
generation of the iC3b metabolite.43 MCP, as well as CFH,
serves as a cofactor for the cleavage of C3b to iC3b by CFI.
Esparza-Gordillo et al.45 demonstrated that two SNPs located
in the promoter region of the MCP gene influence the protein
expression at the surface of the cells. A strong MCP promoter
activity was associated with 547A, 261A alleles, corre-
sponding to the at-risk haplotype for GNC3 and MPGN I,
MCPaaggt. Conversely, the at-risk MCP ggaac haplotype for
aHUS was associated with a low expression of MCP.
Therefore, the endothelial and mesangial cells in GNC3
probably express high levels of MCP. Hence, they will rapidly
inactivate the C3b molecules, deposited because of the
hyperactive C3 convertase stabilized by the C3NeF or not
efficiently regulated in the fluid phase because of mutations
in FH. Generated iC3b will then be deposited in the
subendothelial space, leaving the GBM intact. The level of
MCP expression does not seem to influence DDD. Thus,
differences in MCP variants may explain the wide spectrum
of renal diseases associated with AP dysregulation. Further
functional studies are required to validate this hypothesis and
to understand the protective role of the MCP gaggt haplotype
in GNC3 and DDD patients.
The role of complement AP dysregulation in the pathogen-
esis of the MPGN I remains more debatable as this is an
immune complex disease. In our study, dysregulation of the
AP has been found in 453% of MPGN I patients.
Furthermore, C3NeF detection was as frequent as in GNC3
patients. Our data are in line with the recent report in Cfh/
mice model showing the alteration of systemic and intraglo-
merular immune complex processing in these animals.15 Our
results suggest that MPGN I is an immune complex
glomerulonephritis that may be mediated by AP dysregulation.
In conclusion, identification of acquired or hereditary
defects in the regulation of the AP in the C3 glomerulopathies
as well as in the immune complex–mediated glomerular
diseases illustrates the critical role of complement regulation
in glomerulonephritis. Indeed, in 71% of patients, acquired
(C3NeF) or hereditary abnormalities (mutation) of the
complement alternative pathway are found. Furthermore,
common variations in the MCP gene influence the glomerular
pattern. This suggests that plasma and membrane comple-
ment regulatory protein act in a coordinated manner to
regulate the fluid-phase activation and that genetic back-
ground influences the phenotype of the disease.
MATERIALS AND METHODS
Patients
This study included 141 patients from 45 centers with complement
analysis between August 2000 and June 2009 and a definite diagnosis
of primary MPGN I, DDD, or GNC3 established on renal biopsies.
Seven patients were excluded because of incomplete histological
data. For all cases, detailed clinical and histological data, and
consent for genetic study, were available. Patients with a history of
dysproteinemia, autoimmune disease, and hepatitis B or C were
excluded. Patient care and study conduct complied with good
clinical practice and the Declaration of Helsinki Principles.
Assays for complement components and genetic screening
For all patients, immunological and genetic analyses were performed
at the reference laboratory for the investigation of the complement
system in France (Hoˆpital Europe´en Georges Pompidou). EDTA
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plasma samples were obtained from all patients. Plasma protein
concentrations of C3, FH, and FI were measured as previously
described.46 C3NeF activity was determined as previously described
by assessing the ability of IgG purified from plasma to stabilize the
cell-bound C3b, Bb convertase.47 C3NeF determination was not
available for four patients. Direct sequencing of all CFH, CFI, or
MCP exons and of a set of 10 SNPs within the CFH and MCP genes
was undertaken. The primers and reaction conditions for PCR will
be provided on request (e-mail: veronique.fremeaux-bacchi@
egp.aphp.fr). To determine whether a genetic change is also present
in a control group and therefore more likely to be rare
polymorphism than mutation, we recruited a panel of 100 healthy
subjects for reference. The frequency of alleles 1 and 2 from each
SNP was compared between controls and DDD, GNC3, and MPGN
I groups. Haplotype frequencies were estimated using the expecta-
tion maximization algorithm implemented by the SNPStats software
(available at http://bioinfo.iconcologia.net/SNPstats). We used the
Mann–Whitney test to compare two groups.
Definitions
GFR was estimated using the Modification of Diet in Renal Disease
(MDRD) formula or Schwartz formula for patients o18 years
old.48–51 Kidney disease stage was classified according to the Kidney
Disease Outcomes Quality Initiative (K/DOQI) clinical practice
guidelines.36
Renal biopsy processing
At least one biopsy of native kidney was performed in each patient.
Biopsy specimens for light microscopy were fixed in Bouin’s
solution or alcohol formaldehyde acetic solution, embedded in
paraffin, and cut into 2 mm-thick sections. Sections were stained
with Masson trichrome, hematoxylin and eosin, periodic acid–-
Schiff, and silver methenamine. Samples for immunofluorescence
study were stained with fluorescein isothiocyanate-conjugated
polyclonal antibodies to human m, g, and a heavy chains, and l
and light chains; C3; and C1q (Dako, Glostrup, Denmark), as
previously described.2 Specimens for electron microscopy were fixed
in glutaraldehyde and embedded in epon. A total of 61 biopsies were
centrally reviewed at Necker hospital by an expert pathologist (L-
HN) and, for the others, four main centers were involved (Robert
Debre´, Foch, Lille, and Strasbourg Hospitals). All reports were
reviewed and all MPGN 1 cases with alternative pathway
abnormality were reviewed.
Statistical analysis
Continuous values are reported as means±s.d. Dichotomous data
are presented as percentages. The w2 test or the Fisher’s exact test
was applied for dichotomous and categorical data, the unpaired
t-test was used to compare two continuous variables, and a repeated
measure analysis of variance to compare three continuous variables.
Cumulative renal survival was analyzed by Kaplan–Meier survival
curves and log rank tests. Two-tailed P-values ofo0.05 were regarded
as statistically significant. Statistical analyses were performed using
InStat 3 and Prism 4 software (GraphPad Software, La Jolla, CA).
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